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2Abstract
Podoplanin/PA2.26 antigen is a small transmembrane mucin expressed in different 
types of cancer where it is associated with increased cell migration, invasiveness and 
metastasis. Little is known about the mechanisms that control podoplanin expression. 
Here, we show that podoplanin synthesis can be controlled at different levels. We 
analyzed podoplanin expression in a wide panel of tumour cell lines. The podoplanin 
gene (PDPN) is transcribed in cells derived from sarcomas, embryonal carcinomas, 
squamous cell carcinomas and endometrial tumours, while cell lines derived from 
colon, pancreatic, ovarian and ductal breast carcinomas do not express PDPN
transcripts. PDPN is expressed as two mRNAs of ~2.7 and ~0.9 kb, both of which 
contain the coding sequence and arise by alternative polyadenylation. Strikingly, in most 
of the cell lines where PDPN transcripts were found, no podoplanin or only very low 
levels of the protein could be detected in Western blot.
Treatment of several of these cell lines with the calpain inhibitor calpeptin resulted in 
podoplanin accumulation, whereas lactacystin, a specific inhibitor of the proteasome, 
had no effect. In vitro experiments show that podoplanin is a substrate of calpain-1. These 
results indicate that at least in some tumour cells absence or reduced podoplanin protein 
levels are due to post-translational calpain-mediated proteolysis. We also report in this 
article the identification of a novel podoplanin isoform that originates by alternative 
splicing and differs from the standard form in lacking two cytoplasmic residues 
(YS). YS dipeptide is highly conserved across species, suggesting that it might be 
functionally relevant.
1. Introduction
Podoplanin is a small mucin-like transmembrane protein originally identified as a
3marker of glomerular epithelial (podocyte) cells (Breiteneder-Geleff et al., 1997; 
Breiteneder-Geleff et al., 1999). It was also characterized in distinct biological contexts 
under a variety of names. For example: as T1 α, a marker for alveolar epithelial cells 
(Rishi et al., 1995); as PA2.26, a cell-surface antigen induced in epidermal keratinocytes 
during wound healing and chemical carcinogenesis (Gandarillas et al., 1997; Scholl et 
al., 1999); as gp40/gp36, a main receptor for the influenza C virus (Zimmer et al., 1995; 
Zimmer et al., 1999); and as Aggrus, a platelet aggregation-inducing glycoprotein 
expressed on the surface of tumour cells (Kato et al., 2003). The interest in this 
membrane glycoprotein has increased over the years due to several reasons. First, it is a 
specific marker for the lymphatic endothelium (Breiteneder-Geleff et al., 1999). 
Second, podoplanin null mice die at birth due to malformation of alveoli (Ramirez et 
al., 2003). These mice also show defects in the lymphatic vascular system (Schacht et 
al., 2003). Third, podoplanin expression is up-regulated in a variety of human cancers, 
including testicular germ cell tumours (Schacht et al., 2005; Kato et al., 2005), 
mesotheliomas (Chu et al., 2005) and different types of carcinomas (Kato et al., 2003; 
Kato et al., 2005; Martin-Villar et al., 2005; Schacht et al., 2005; Wicki et al., 2006).
Several data indicates that podoplanin plays an important role in malignant 
progression (reviewed in Wicki and Christofori, 2007). Kato and co-workers have 
proposed a prometastatic function for podoplanin based on its ability to induce 
platelet aggregation associated with the development of arrested tumour emboli (Kato 
et al., 2004). Moreover, we have demonstrated that podoplanin can promote an epithelial 
to mesenchymal transition (EMT) associated with increased cell migration, invasion 
and metasasis (Martín-Villar et al., 2006; Ramirez et al., 2003; Scholl et al., 2000; 
Scholl et al., 1999). This phenotypic conversion depends on the binding of the 
cytoskeletal-membrane linker ezrin to the cytoplasmic domain of podoplanin, which 
4leads to the activation of RhoA GTPase (Martín-Villar et al., 2006). Nevertheless, other 
studies have shown that podoplanin destabilizes cell-to-cell adhesion and promotes cell 
migration without inducing EMT (Martin-Villar et al., 2005; Wicki et al., 2006).
Due to its role in tumour progression the regulation of podoplanin expression is of 
great interest. Several cDNA sequences encoding an identical 162-amino acids human 
podoplanin polypeptide have been reported by us and others (Ma et al., 1998; 
Zimmer et al., 1999; Martin-Villar et al., 2005). Comparison of these sequences with 
genomic data bases predicts 6 exons and 5 introns within the PDPN gene locus (Martin-
Villar et al., 2005). The first exon contains a 5’ UTR of about 203 nt before the ATG 
initiation codon. The last exon contains the termination codon followed by a long UTR 
of 1 769 nt which includes a 200 nt AluSc sequence in the reverse orientation at the 
3’ end. The PDPN gene is transcribed into two mRNAs of about 2.7 kb and 0.9 kb in 
normal human tissues (Kriehuber et al., 2001; Martin-Villar et al., 2005). While the 
larger transcript fits the 2 737 nt size reported by us for the PDPN cDNA sequence 
(Martin-Villar et al., 2005), the origin of the 0.9 kb was unknown until now.
In this article, we show that podoplanin expression is regulated by a number of 
mechanisms. First, alternative polyadenylation signals account for the two 2.7 kb and 
0.9 kb PDPN transcripts expressed in normal tissues and cell lines. Second, an 
alternative splicing mechanism gives rise to a PDPN mRNA form encoding a shorter 
(160-amino acids) protein lacking two residues at the C-terminus. Third, in several 
human cell lines podoplanin protein expression is downregulated by proteolytic 
degradation mediated by calpain.
2. Materials and methods
2.1. Cell culture
Cell lines were grown in DMEM supplemented with 10% FBS, 1 unit/ml 
5penicillin, 0.1 mg/ml streptomycin, and 2 mM L-glutamine. The neuroblastoma cell line 
SHSY5Y and the embryonal carcinoma cell line NCCIT were cultured in RPMI 
medium with 15% FBS.
MCF10A cells were cultured in DMEM:F12 (1:1), supplemented with 10% goat 
serum, 10 μg/ml insulin, 20 ng/ml EGF, 0.5 μg/ml hydrocortisone, and 0.1 µg/ml 
cholera toxin. NIHOVCAR-3 cells were grown in DMEM with 10% FBS. All cells 
were routinely cultured in 5% CO2 at 37ºC. Pancreatic carcinoma cell lines (IMIM-
PC-1, IMIM-PC-2, Panc-1, SKPC-1 and RWP-1), were kindly provided by Dr. F.X. 
Real (Institut Municipal d’Investigacio Medica, Barcelona, Spain); human breast 
(MCF-7, MDA-MB-231, MDA-MB-435, BT-549 and CAMA-1), ovarian 
(NIHOVCAR and SKOV3) and endometrial (KLE, HEC1B, AN3Ca, HEC-265, 
Ishikawa, SK-UT1 and SK-UT1B) carcinoma cell lines by Drs. D. Sarrió and G. 
Moreno-Bueno (Centro Nacional de Investigaciones Oncológicas, Madrid, Spain); 
embryonal carcinoma cell lines (NCCIT and NTERA-2) by Dr. M.P. de Miguel (Cell 
Engineering Laboratory, Hospital Universitario La Paz, Madrid, Spain); and squamous 
cell carcinoma cell lines HN1 9 and HN30 by Dr. S Gutkind (National Institute of 
Dental and Craniofacial Research, NIH, Bethesda, USA).
HN30, SCC13 and HT1080 cells were treated with 50µM N-acetyl-Leu-Leu-
Norleu-al (ALLN) (Calbiochem) and 10µM MG132 (Calbiochem) to inhibit both the 
proteasome and calpain proteolytic activities. To inhibit specifically either the 
proteasome or calpain function, cells were treated with 10 µM Lactacystin or 50µM 
calpeptin (Calbiochem), respectively. The inhibitors were dissolved in 
dimethylsulfoxide (DMSO) and cells treated with vehicle only were also included as 
controls. After 14h of incubation, cell lysates were obtained in RIPA buffer (0.1% 
SDS, 0.5% sodium deoxycholate, 1% NP-40, 150 mM NaCl, 50 mM Tris-HCl pH 
67.5) and a cocktail of protease inhibitors and analysed by Western blotting.
2.2. Western blot analysis and antibodies
Cell lysates were obtained in RIPA buffer and analyzed by western blotting after
electrophoresis in 10% SDS-PAGE, as described previously (Martin-Villar et al., 
2005). Two different anti-human podoplanin antibodies were used. Ab1 is a polyclonal 
antibody against a synthetic peptide comprising amino acids 37–5 1 (P37-51) of the human 
podoplanin ectodomain (Martin-Villar et al., 2005), and Ab2 is a polyclonal anti-human 
podoplanin antibody against the entire podoplanin ectodomain purchased from Cell 
Sciences. Ab1 and Ab2 were used at a dilution of 1:8000 and at 1 µg/ml, respectively. 
As a control, Ab1 was preincubated with an excess of either P37-51 (3 µg/ml) or an 
unrelated peptide, for 30 min, in order to verify the specificity of recognition (Martin-
Villar et al., 2005). Antibodies for α-tubulin (DM1A) and -actin (both from Sigma-
Aldrich) were used at 1:10 000 dilution; antibodies for Smad2/3 (Cell Signaling) and β-
catenin (BD Biosciences) were used at 1:1 000 and 1:100, respectively, and antibody 
for Spectrin (Millipore, MAB1622) was used at 2x10-2 µg/ml. Horseradish-peroxidase-
conjugated sheep anti-mouse (Amersham Biosciences) and goat antirabbit (Biosciences) 
IgGs were used as secondary antibodies.
2.3. In vitro digestion with calpain-1
NCCIT and MDCK-PDPN-EGFP (Martín-Villar et al., 2006) cells were lysed 
with RIPA buffer containing 1 mM EDTA, 1 mM EGTA, 1 mM PMSF, 10 µg/ml 
aprotinin and 10 µg/ml pepstatin. Extracts were centrifuged at 14 000 rpm for 15 min. 
Reaction mixtures containing 50 mM TrisCl, pH 7.5, 5 mM DTT, 2.5 mM CaCl2 and 
30 µg of protein., were digested with various amounts of calpain-1 (Calbiochem), as 
shown in Fig. 5C. Digestions were carried out for 30 min at 37ºC and analysed by 
western blotting.
72.4. Northern-blot and RT-PCR analysis
70-80% confluent cells were used to obtain total RNA with the Rneasy (Qiagen) 
kits. Twenty µg of total RNA from different cells lines were electrophoresed in 1% 
agarose gels with 0.41 M formaldehyde and transferred downwards with 10xSSC as 
described (Chomczynski and Mackey, 1994). Hybridization was done with 106
cpm/ml of 32P-labeled PDPN cDNA (Martin-Villar et al., 2005) using the conditions 
of Church and Gilbert .
Reverse transcription was performed at 37°C for 2 hours using the enzyme from 
avian myeloblastosis virus (Promega), 2µg of total RNA extracted from the cell lines, 
and random hexadeoxynucleotides as primers. The products of the reaction were used 
for PCR (30 cycles: 94°C for 1 minute, 59°C for 1 minute 30 seconds, and 72°C for 1 
minute 30 seconds) in a Gene Amp PCR system 2400 (Perkin Elmer, Foster City, 
CA). For human podoplanin amplification the following oligonucleotides were 
used: 5’- CGGGAACGATGTGGAAGGTGTCA (forward) and 5’-
GGGACAGGGCACAGAGTCAGAAAC (reverse). Oligonucleotides for glyceraldehyde-
3 - phosphate dehydrogenase (GAPDH) amplification have been described elsewhere 
(Scholl et al., 2000).
2.5. Determination of the Origin of Transcription
Primer extension was done with oligodeoxynucleotides 5’-
GGAAAATTAAAAAGCACCGCGGCCACAG (positions -57 to -84 from the 
initiation codon) and 5’-GTTGAGTTGTTGCTCTCCTGGGGGCCGAGC (positions -8 
to -37 from the initiation codon). Oligodesoxynucleotides (10 pmol) were labelled 
with 50 Ci [-32P]ATP using polynucleotide kinase as described by Sambrok and 
Russell . The primer extension reaction was carried out with 15 µg of NCCIT total 
RNA. Annealing, reverse transcription and electrophoresis of the products in 6% 
8acrylamide gels in the presence of 7M urea was essentially done as described 
(Sambrook and Russell, 2001).
2.6. 3’-RACE
To characterize polyadenylation sites, we used total RNA from NCCIT or 
NTERA2 cells and normal human lung tissue (Tumour Tissue Bank of the Hospital 
Universitario La Paz, Madrid) because podoplanin is normally expressed in this tissue 
(Martin-Villar et al., 2005). Fifteen µg of RNA was used for first strand cDNA 
synthesis using MMLV Reverse Transcriptase (Promega) and random 
hexadeoxynucleotides as primers, in a 20 µl volume reaction according to the 
manufacturer’s instructions. One µl of these reactions was used for a first PCR 
using primer 6972-F (5’- CACACAGACAACAGTTGAGAA, bases 348-3 68 from 
the initiator ATG) and oligo(dT)- M13D (5’-
CATGTTGTAAAACGACGGCCAG(T)24), with the following amplification 
scheme: 94°C for 3 min, 30 cycles of 94°C for 50 sec, 48°C for 50 sec and 72°C for 90 
sec, followed by 72°C for 7 min. The reaction mixture (50 µl) contained 1 unit of Tth 
DNA polymerase (BioTools, Madrid, Spain), 1 µM primers and 0.2 mM dNTPs. One 
µl of the first PCR reactions were amplified again with INT-F primer (5’-
CAATCATCGTTGTGGTTATGC, bases 440-460 from the initiator ATG) and M13 
universal direct primer using the same amplification protocol. PCR products were 
ligated to pGEM-Teasy vector (Promega) overnight at 16ºC and plated on 100 
µg/ml ampicilin agar plates. Positive colonies were detected by colony PCR with 
M1 3 direct and reverse universal primers in a 20 µl reaction volume using the above 
conditions. Ten µl of the reactions were electrophoresed in 1% agarose gels; the 
remaining volume was diluted five fold with water and 7 µl of the dilution 
sequenced with the M13-R universal primer in an ABI 377 sequencer.
9To study the distal polyadenylation site we carried out the first PCR with
oligonucleotide DISTAL- 1 -F (5’ -GAAACCAAGAGCCAGTTGTCC, positions 1 617-1 
637) instead of 6972-F, and the second PCR with DISTAL-3-F (5’-
CATATTTGAACACCAGCTGATTGAGAGAAGG, positions 2 459-2 489).
2.7. Sucrose gradient fractionation of polysomes
Sucrose gradient fractionation was performed essentially as described by del Prete 
et al. Fractions were collected from the top, digested with proteinase K and extracted 
with phenol:chloroform. RNA was recovered by ethanol precipitation and analysed by 
Northern blotting as described above. 
2.8. Confocal immunofluorescence analysis
Immunofluorescence detection of human podoplanin in KLE cells was 
performed on cells fixed with 3.7% formaldehyde in PBS, permeabilized with 0.05% 
Triton X-100. The podoplanin polyclonal antibody Ab1 was used at 1:500 dilution. 
Alexa-488-labeled anti-
rabbit (Molecular Probes) IgG was used as secondary antibody. Staining of nuclei 
was performed in a solution of 4’,6-diamino-2-phenilindole (DAPI, 1 µg/ml; Sigma-
Aldrich). Confocal laser scanning microscopy was performed in a Leica TCS-SP2 
microscope (Leica Microsystems, Heidelberg GmbH). Images were taken using a 63x oil 
(NA 1.32) immersion objective and assembled using Leica Confocal Software 2.0.
3. Results and discussion
3.1. Podoplanin expression in human cell lines
The expression of podoplanin was analyzed in a wide panel of human normal 
and tumour cell lines by RT-PCR and Western immunoblotting (Fig. 1 and Table 1). 
While no expression was found in cell lines derived from colorectal (4/4), pancreatic 
(5/5), breast (5/5) and ovarian (2/2) carcinomas, significant levels of PDPN
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transcripts were observed in cultured cells derived from sarcomas (2/2), embryonal 
carcinomas (2/2), squamous cell carcinomas (6/7), prostate carcinoma (1/1) and 
endometrial tumours (3/7). PDPN mRNA expression was also detected in several non-
tumour cell lines (Fig. 1A, Table 1). In the PDPN-expressing cell lines, Northern blot 
analysis revealed the presence of two mRNA species of about 2.7 and 0.9 kb (Fig. 1B), 
as previously reported for normal tissues (Kriehuber et al., 2001; Martin-Villar et al., 
2005). Interestingly, in many of the cell lines expressing PDPN transcripts, very low 
levels or a complete absence of protein was found by Western blot analysis (Fig. 1C 
and Table 1). In fact, only 2 cell lines out of 17 containing transcripts had high 
levels of podoplanin protein: KLE, NCCIT (derived from a germ cell tumour and an 
endometrial carcinoma, respectively). For Western blot studies we used two distinct 
antibodies that specifically recognize the podoplanin ectodomain, as described in 
Materials and methods. Overall, there was a good correlation between the results 
obtained with both antibodies, ruling out the possibility that unsuccessful protein 
detection in cell lines expressing PDPN transcripts was due to the antibody. A broad 
band of 35-50 kDa was found in the blot of NCCIT cells (Fig. 1C), likely indicating a 
highly heterogeneous pattern of protein glycosylation (Marks et al., 1999; Martin-
Villar et al., 2005) and/or different states of processing (see below). Confocal 
immunofluorescence analysis showed that podoplanin was concentrated at the cell surface 
on plasma membrane protrusions (Fig. 1D), as previously described (Martín-Villar et al., 
2006; Martin-Villar et al., 2005; Scholl et al., 1999).
3.2. Transcriptional heterogeneity of podoplanin
Analysis of NCBI PDPN cDNA sequences revealed the presence of several 
ESTs compatible with the existence of multiple transcription start sites (Martin-
Villar et al., 2005), a fact recently confirmed by others (Hantusch et al., 2007). We 
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used primer-extension analysis to map the start site(s) for PDPN gene transcription 
in NCCIT cells (Fig. 2A). The major transcription start site (designated +1) was 
located 94 bp 5’ upstream from the ATG start codon. This site differs from that 
reported by Hantusch and colleagues in MG63 osteosarcoma cells, in which most 
transcription initiates at a position 107 bp upstream from the site determined by us. 
Thus, transcription initiation of PDPN gene can take place over at least a ~100 bp 
region, a typical situation in TATA-less and CpG-island enriched promoters (Sandelin 
et al., 2007). We have cloned 2 070 bp of the 5’ flanking region and performed 
reporter gene assays by introducing targeted deletions in the sequence. Our results 
were essentially similar to those reported before (Hantusch et al., 2007), showing 
that the 5’ flanking region contains motifs that provide basic podoplanin activity and 
that silencing motifs are located in a 300 bp region located 700 bp upstream the ATG 
start codon (data not shown).
While the larger PDPN transcript of ~2.7 kb fits the estimated size of the 
reported full-length podoplanin mRNA (Martin-Villar et al., 2005), the shorter mRNA 
species of ~0.9 kb could represent an alternatively polyadenylated form. In order to test 
this possibility, we performed Northern blot analysis with RNA isolated from the cell 
lines HEK-293T and NTERA-2 using probes containing either the coding sequence 
(A), or most of the 3’-UTR (from positions 989 to 2 152, B) (Fig. 2B, upper panel). 
While probe A detected both mRNAs, probe B only recognized the larger transcript 
(Fig. 2B, lower panel), indicating that the 0.9-kb transcript ends before or 
immediately after position 989. To define the exact sites of polyadenylation of both 
mRNAs, we conducted 3’-RACE experiments (using 52 clones obtained from lung 
RNA and 4 clones from NCCIT cells RNA). Fig. 2C shows the sequence around the 
polyadenylation site for the short (upper sequence) and long (lower sequence) mRNA 
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species. It is noteworthy that the proximal polyadenylation signal is not the canonical 
one, and has not been described before (Hu et al., 2005). We have denoted the 
proximal polyadenylation signal as ATTAYA because we found T in the fifth position 
in the lung but C in the NCCIT clones.
Polyadenylation of mRNAs requires the binding of at least two trans-acting 
factors: the Cleavage and Polyadenylation Specificity Factor (CPSF) that binds the 
Polyadenylation Signal (PAS), and the Cleavage Stimulation Factor (CstF), which 
interacts with U- and U/Grich elements downstream the polyadenylation site (Chen 
and Wilusz, 1998). However, auxiliary upstream elements (AUE) have been 
described in a variety of systems (Hu et al., 2005). Using the PolyA_DB2 server (Lee 
et al., 2007) several putative elements can be detected in both PDPN mRNA termini, 
either upstream or downstream of the polyadenylation site. It is interesting to note that 
strong AUEs are found in the small PDPN mRNA. One of them, AUUUGUAAC, is 
identical to that found in the SV40 late polyadenylation signal (Schek et al., 1992)
and is not present in the large PDPN mRNA. Similar sequences have been described in 
other systems (Hall-Pogar et al., 2005; Natalizio et al., 2002), located up to 60 nt before 
the polyadenylation site. The fact that the distal polyadenylation site lacks this efficiency 
element could be the explanation for the approximate near similar proportion of both 
mRNAs expressed in tissues and cell lines, as the strength of the distal versus the 
proximal PAS could be balanced by the presence of strong AUEs upstream the 
proximal polyadenylation site.
3.3. Identification of a novel podoplanin isoform arising by alternative splicing
During the 3’-RACE analysis described above, we observed the presence of 
an additional transcriptional variant indicative of an alternate spliced podoplanin form 
(PDPNΔYS). Both podoplanin isoforms share the extracellular and transmembrane 
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domains, but the PDPN-ΔYS form lacks two residues (YS) from the cytoplasmic tail 
(Fig. 3A). Although the cDNAs derived from the 3’ RACE analysis showed an equal 
frequency of occurrence for the standard and ΔYS isoforms in our samples (lung and 
NCCIT cells), human EST databases predict a higher frequency of the standard 
isoform (Fig. 3B). This difference could be explained by the limited number of 
sequences analyzed in this article. Interestingly, the mouse Pdpn gene contains the 
same donor/acceptor sites in the boundary between exon 5 and intron 5 that would 
give rise to a similar variant lacking two residues (FS) of the endodomain. However, 
such a podoplanin form is not recorded in mouse databases, and we have been unable 
to detect it by 3’ RACE experiments using different mouse tissues (data not shown). 
In this regard, it is interesting to note that recent results show a low conservation of 
alternative spliced forms between humans and mice (Takeda et al., 2008).The 
functional relevance of the human podoplanin ΔYS isoform is unknown at present. 
The two amino acids YS are highly conserved across species from fishes to primates, 
with the exception of mice and rats in which phenyalanine substitutes tyrosine (Fig. 
3C), although another rodent, Chinese hamster, has tyrosine instead of phenylalanine 
in this position. The strong conservation of these two amino acids suggests they might 
play an important role in the biology of podoplanin. Moreover, a recent study 
describes a number of genes, including PDPN, that appear to have alternative 
spliced formsdifferentially expressed in lung adenocarcinomas and normal tissue 
(Xi et al., 2008).
3.4. Podoplanin stability is post-translationally regulated by calpain
To ascertain whether the lack of podoplanin protein in cell lines that contained 
PDPN transcripts was due to a post-translational mechanism, we studied the 
association of PDPN mRNAs with polysomes, an indication that mRNAs are being 
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translated (Pradet-Balade et al., 2001; Qin et al., 2007). A representative analysis is 
shown in Fig. 4, showing that both PDPN mRNAs are being translated.
The fact that PDPN mRNAs are bound to the polysomal fractions is a 
strong indication that podoplanin is being translated. We hypothesized then, that 
podoplanin, once synthesized is being degraded. Since the proteasome is the main 
pathway for protein degradation in eukaryotic cells, we treated HN30, SCC13 and 
HT1080 cells with different proteasome inhibitors. Fig. 5A shows a representative 
experiment with HN30 cells. ALLN and MG132, but not lactacystin allowed the 
accumulation of podoplanin. As ALLN and MG132 are also inhibitors of calpain 
(Figueiredo-Pereira et al., 1994; Tsubuki et al., 1996), we treated cells with 
calpeptin, a specific inhibitor of calpains. As shown in Figs. 5A and B, calpeptin 
also allows podoplanin accumulation in all the cell lines tested, although with 
different efficiencies. In these assays we also monitored the accumulation of -
catenin and Smad2, two proteins known to be degraded by the 
proteasome(Massague et al., 2005; Moon, 2005) as a control of proteasomal activity.
Taken together, the above results indicate that calpain-mediated proteolysis could be 
an important pathway to regulate podoplanin turnover in certain types of tumour 
cells.
To analyze whether podoplanin is indeed a direct substrate of calpain NCCIT 
and MDCK-PDPN-EGFP extracts were treated with increasing amounts of calpain-
1. As shown in Fig. 5C, calpain-1 was able to partially proteolyze podoplanin 
producing the accumulation of smaller fragments. As a control, spectrin, a well 
known calpain substrate was found to be proteolyzed in the same assay.
Structural and sequential determinants for substrates of calpain are not well 
defined, although PEST sequences (sequences rich in Pro, Glu/Asp and Ser/Thr 
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residues, see Rechsteiner and Rogers, 1996) could be involved. In this regard, 
podoplanin has a moderate PEST sequence between positions 79 to 91, as deduced 
by the PESTfind server (http://www.at.embnet.org/toolbox/pestfind). In addition to 
this sequence preference, calpain cleavage sites appear to be located in disordered 
segments of its substrate (Tompa et al., 2004).
Calpains are involved in a variety of physiological and pathological processes 
including cell attachment, spreading and migration(see Franco and Huttenlocher, 
2005; and Lebart and Benyamin, 2006 for recent reviews). Podoplanin is known to 
promote surface protrusions (Martin-Villar et al., 2005; Wicki et al., 2006) and it has 
been also detected in the tail of migrating cells during contraction and detachment of 
the rear (Martín-Villar et al., 2006). The rationale for calpain-mediated proteolysis 
of podoplanin, as occur with other proteins involved in cell motility, could be to 
ensure proper timing and localization of highly dynamic multi-molecular complexes 
in order to be continually regulated.
In conclusion, we detect a variety of regulatory mechanisms for podoplanin 
expression, both transcriptional (multiple initiation sites, alternative splicing and 
polyadenylation) and post-translational (proteolytic processing). An important 
question now is to understand the different cell-specific events we detect, like the 
presence or absence of PDPN mRNA or protein in the cells. It is likely that this 
calpain-mediated proteolytic processing observed in cell lines also takes place in 
normal and/or tumoural tissue. Therefore, caution should be taken in the 
analysis of podoplanin expression in gene profiling studies in primary tumours, as 
podoplanin protein determination may show different patterns of those found for 
mRNA. 
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FIG. LEGENDS
Fig. 1. Analysis of podoplanin mRNA and protein expression in human cell lines. 
Podoplanin mRNA expression was monitored by RT-PCR (A) or Northern blot analysis 
(B). GAPDH and were used as controls for the amount of RNA and -actin for the 
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amount of protein. C, Western blot analysis using antibody Ab1 (see Materials and 
methods). HeLa cells stably transfected with PDPN cDNA (HeLa-PDPN) were used 
as a positive control. Also, -tubulin was used as a control for the amount of protein 
loaded in the gel. D, Confocal immunofluorescence detection of podoplanin in KLE 
cells. Horizontal (xy) optical sections are shown in the upper panel and inset (apical 
domain). The lower panel shows a section in a vertical (xz) optical plane.
Fig. 2. Analysis of transcriptional regulation of PDPN expression. A, Determination of 
the transcriptional start site in NCCIT cells. Primer extension of NCCIT RNA was carried 
out as described in Materials and methods. The Fig. shows the autoradiography of the 
gel. Lane 1, elongation reaction made in the presence of 10% DMSO for 1 h at 42°C; 
lane 2, the same incubation without DMSO; lane 3, incubation at 60°C, without 
DMSO; lane 4, no RNA added. A, C, G and T are sequencing reactions made with 
the same 32P-labelled deoxyoligonucleotide using as template a plasmid with 2 kb of 5’ -
upstream sequence from the initiator ATG. B, Alternate polyadenylation signals 
account for the expression of 0.9 and 2.7 kb mRNAs. In the upper panel a diagram of 
the PDPN transcript is shown, containing the open reading frame as well as the two 
polyadenylation signals and the Alu sequence. The locations of the probes used for 
the Northern analysis and the estimated sizes of the two mRNAs are also shown in 
the upper panel, as well as the expected sizes of the two mRNAs. The lower panel 
shows the hybridization with probes A and B of total RNA from the indicated cell 
lines. C, Sequence surrounding the proximal (upper row) and distal (lower row) 
polyadenylation sites. Numbers on the left of the sequences are coordinates from 
GeneBank AY194238; numbers above or below the sequences refer to the poly(A)
addition site, indicated by vertical arrows. Bold underline shows the binding sites for 
CstF; double underline and italics shows the AUE in the proximal polyadenylation 
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region.
Fig. 3. Differential splicing in the PDPN gene. A, Diagram showing the sequence 
boundaries of exons 5 and 6 (capital letters) and intron 5 (small letters). Double and 
single underlines show the two possible donor sites. B, ESTs spanning the splicing 
region were obtained from Unigene (http://www.ncbi.nlm.nih.gov/UniGene/ build 
#208) or detected by 3’-RACE using lung or NCCIT RNA. C, Amino acid sequence of 
podoplanin cytoplasmic tail from different vertebrates.
Fig. 4. Polysome analysis of HEK293T cells. Gradients and extracts were prepared 
as described in Materials and methods. Gradients were fractionated from the top; the 
“free” fractions correspond to ribonucleoproteins, 40S, 60S subunits and single 
ribosomes; “bound” refer to polysome-containing fractions. A, methylene blue staining 
of the membrane; B, autoradiography. Small arrows in panel point to 28S (upper) and 
18S (lower) rRNAs, respectively; C, quantification of the hybridisation shown in B. 
Open circles, 0.9 kb mRNA; filled circles, 2.7 kb mRNA; dashed line, ratio 28S/18S 
calculated from the methylene blue staining.
Fig. 5. Inhibition of calpain proteolytic activity stabilises podoplanin expression. A, 
Western blot analysis of podoplanin expression in HN30 cells after treatment with the 
indicated proteasome and/or calpain inhibitors. Cells were treated with the 
inhibitors or vehicle (DMSO) as described in Materials and methods. Values below 
the upper blot represent podoplanin expression levels relative to -actin levels 
quantified by densitometric analysis. B, Comparison of the levels of podoplanin 
accumulated after treatment of HN30, HT1080 and SCC13 cell lines with calpeptin. 
Podoplanin levels relative to -tubulin levels were quantified by densitometry. Values 
in the table at the bottom were calculated by subtracting the levels of podoplanin 
synthesized in basal conditions (DMSO) from those obtained after treatment with 
24
calpeptin. An arbitrary value of 100 was given to HN30. C, In vitro digestion of 
NCCIT and MDCK-PDPN-EGFP extracts with calpain-1. Numbers above the upper 
blots represent the units of calpain-1 in the reaction. -actin was used as a control for 
the amount of protein.
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Table 1. Expression of podoplanin mRNA and protein in human cell lines 
Origin Cell line mRNA Protein
Noncancerous
Epidermal keratinocytes HaCaT -- --
Embryonic Kidney HEK-293T + +/-
Mammary epithelium MCF10A + +/-
HBL100 - --
Lung primary fibroblasts NP + --
Cancerous
Colon carcinoma SW480 -- --
LOVO -- --
HT29-P -- --
HT29-P-LMN -- --
Pancreatic carcinoma IMIMPC-1 -- --
IMIMPC-2 -- --
PANC-1 -- --
SK-PC-1 -- --
RWP-1 -- --
Ductal breast carcinoma MCF-7 -- --
MDA-MB-231 -- --
MDA-MB-435 -- --
BT-549 -- --
CAMA1 -- --
Ovarian carcinoma NIHOVCAR-3 -- --
SKOV3 -- --
Endometrial carcinoma KLE + +
HEC 1B -- --
AN3Ca -- --
HEC-265 -- --
Ishikawa -- --
Endometrial carcinosarcoma SK-UT1 + +/-
SK-UT1B + +/-
Squamous cell carcinoma
Skin SCC13 + +/-
Oral cavity HN19 + --
HN30 + --
SCC9 + --
FaDu + +/-
Detroit 562 + +/-
Cervix HeLa -- --
Prostate carcinoma (brain metastasis) DU-145 + +/-
Embryonal carcinoma NCCIT + ++
NTERA-2 + +
Sarcoma
Fibro- HT1080 + +/-
Osteo- SAOS-2 + --
Neuroblastoma SK-N-MC -- --
SH-SY5Y -- --
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±, indicates low level or non consistent results between replicates. mRNA and protein 
were determined by RT-PCR and Western immunoblotting, respectively. For Western 
blot studies two distinct podoplanin antibodies that recognize the protein ectodomain 
were used, as described in Materials and methods.
Reviewer #1:
1) As explained in the text, we used calpains inhibitors because the proteasome 
inhibitors we used in first place were also inhibitors of calpains, and we wanted to 
be sure about the proteolytic system involved in podoplanin degradation. Although 
the reviewer states that podoplanin is not degraded by calpains, our results in Fig. 
5C show, on the contrary, that podoplanin is indeed a direct substrate of this family 
of proteases.
2) Discussion about the up-regulation of podoplanin after treatment with calpains 
inhibitors. We think that the phenomenon we see is not up-regulation, but
stabilization of the protein. In the last paragraphs of the manuscript we discuss the 
framework in which podoplanin is proteolyzed by calpain, in a process necessary to 
build up and dismantle multi-molecular protein complexes needed to fulfil the 
dynamics of actin assembly and disassembly needed in cell motility.
Reviewer #2
1) We have changed Fig. 1 in a way that, first, uses the same cell lines for Northern 
and Western blot analysis, including the cell lines requested by the reviewer, and 
second, we have arranged them in the same order as they appear in Table 1.
2) We have had great difficulties with the polysomal gradients for HN30 cells. 
These cells express very low levels of podoplanin mRNA and even though all the 
procedures were done in the presence of several RNAse inhibitors, is was difficult 
to obtain publication-quality gradients. So we decided to do gradients for other 
podoplanin-expressing cells (NCCIT, HEK293T and HT1080) in addition to HN30. 
In all cases we got PDPN mRNAs in the polysome fractions, so weshow here the 
HEK293T results as an example.
3) The experiment suggested by the reviewer was actually done, However 
HEK293T cells did not accumulate podoplanin protein when treated with calpeptin 
(or lactacystin). This result suggest that other mechanisms may be relevant in this 
cell type.
In connection with points 2 and 3, we are aware (and we mention it at the end of the 
manuscript) of the different behaviour of distinct cell types in relation with the 
regulatory processes we are describing, namely differences in amount of mRNA, or 
protein or response to the treatments. This is an interesting subject, but we think is 
out of the scope of this manuscript, that addresses more specifically the several 
levels of regulation of podoplanin expression.
* Response to Reviewers
4) As suggested by the reviewer, we have performed experiments in order to 
demonstrate that podoplanin is a direct substrate of calpain (Fig. 5C)
5) As mentioned in the response to reviewer #1, we have discussed more in depth
the framework in which podoplanin could be regulated by calpains.
Minor comments (although pages and lanes do not necessarily coincide now):
Page 7, lane 13: was essentially done as described. Corrected
Page 9, lane 22: ..., there was a good correlation between the results...Corrected
Page 11, lane 10: add some remarks why you used lung RNA. In the manuscript we 
state that podoplanin is a protein found in lung; furthermore, the availability of 
this material in the Tumour Tissue Bank was also an important reason to use lung 
tissue, although we think is not so important as to mention it explicitly in the 
manuscript
Page 12, lane 12f: discuss more concise the concluding remarks of this section. What’s 
the point? Paragraph changed
Page 12, lane 16: rephrase  "the same splicing sequences in donor/acceptor sites." 
paragraph changed
Page 12, lane 12/13: write phenylalanine and tyrosine instead of F and Y Corrected
Page 12, lane 22: .that another rodent has tyrosine. Corrected
Page 13, lane 1: what is serine-161? If you number the amino acids, do that as well for 
the F-160  and Y-159. Why do you think that Ser-161 is important? Discuss this point. 
Paragraph changed
page 13, lane 12: Rephrase the sentence summarizing the polysome fractionation 
results. Possibly then start a new paragraph with more clear introductory words. 
Paragraph changed
Page 13, lane 14: rephrase to ".with the proteasome inhibitors ALLN and MG132 
that.and  with the specific..". Describe more detailed the mode of action of ALLN and 
MG132 (plus literature). Paragraph changed
Page 13, lane 21: ..as a control of proteasomal degradation activity (Fig. 5A). 
Corrected
Figure legends: 
Fig. 4, lane 3: explain RNP Corrected
Fig. 4, lane 5: .in panel B point to 28S Corrected
Reviewer #3
1) The reviewer asks for a more extensive discussion of the possible biological 
relevance of the findings. With regard of the YS isoform we are starting now to 
study its properties in well known aspects of podoplanin  function (as cell motility 
and epithelial-mesenchimal transition). However our findings are very preliminary 
to make any statement in a publication. Regarding to the rationale of podoplanin 
calpain-mediated proteolysis, we have discussed it in the response to reviewer #1.
With respect to minor comments,
- Page 3, Introduction: "...glycoprotein expressed ON the surface of tumour 
cells (...). The interest IN this membrane glycoprotein..." Corrected
- Page 6, Materials and Methods, paragraph 2.2: instead of giving antibody 
dilutions (from unknown original concentrations), it would be more useful to know the 
actual concentrations of the antibodies used. We have included concentrations 
whenever possible. However,Ab1 was produced by us and is not purified.
- Page 7, Materials and Methods, paragraph 2.4: some more details on the 
labelling with polynucleotide kinase would be desirable. Paragraph added
- Page 11, Results and Discussion, paragraph 3.2: typo "mRNA spePcies" 
(center of page) Corrected
- Page 13, Results and Discussion, paragraph 3.4: two references are still in 
preliminary format "{... #727 ... #728...}" Corrected
- Page 13, Results and Discussion, paragraph 3.4: typo "stabilYsed" (bottom of 
page) Corrected
- Page 21, Figure Legends, Fig. 2: vertical arrows are mentioned which are not 
present in the figure. The arrows are present in the diagram, although perhaps not 
big enough, as they are of the same size of the other letters used. However, its place 
is also marked by a “+A”, so we think it is not necessary to make them larger.
- Page 21, Figure Legends, Fig. 4: No indication about the difference between 
empty and filled circles in panel C of the figure. Corrected
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Table 1. Expression of podoplanin mRNA and protein in human cell lines  
Origin Cell line mRNA Protein 
Noncancerous    
 Epidermal keratinocytes HaCaT -- -- 
 Embryonic Kidney HEK-293T + +/- 
 Mammary epithelium MCF10A + +/- 
 HBL100 - -- 
 Lung primary fibroblasts NP + -- 
    
Cancerous    
 Colon carcinoma SW480 -- -- 
 LOVO -- -- 
 HT29-P -- -- 
 HT29-P-LMN -- -- 
 Pancreatic carcinoma IMIMPC-1 -- -- 
 IMIMPC-2 -- -- 
 PANC-1 -- -- 
 SK-PC-1 -- -- 
 RWP-1 -- -- 
 Ductal breast carcinoma  MCF-7 -- -- 
 MDA-MB-231 -- -- 
 MDA-MB-435 -- -- 
 BT-549 -- -- 
 CAMA1 -- -- 
 Ovarian carcinoma NIHOVCAR-3 -- -- 
 SKOV3 -- -- 
 Endometrial carcinoma KLE + + 
 HEC 1B -- -- 
 AN3Ca -- -- 
 HEC-265 -- -- 
 Ishikawa -- -- 
    
 Endometrial carcinosarcoma SK-UT1 + +/- 
 SK-UT1B + +/- 
 Squamous cell carcinoma    
  Skin SCC13 + +/- 
  Oral cavity HN19 + -- 
 HN30 + -- 
 SCC9 + -- 
 FaDu + +/- 
 Detroit 562 + +/- 
  Cervix HeLa -- -- 
 Prostate carcinoma (brain metastasis) DU-145 + +/- 
 Embryonal carcinoma NCCIT + ++ 
 NTERA-2 + + 
 Sarcoma    
  Fibro- HT1080 + +/- 
  Osteo- SAOS-2 + -- 
 Neuroblastoma SK-N-MC -- -- 
 SH-SY5Y -- -- 
Table 1
 2
±, indicates low level or non consistent results between replicates. mRNA and protein were 
determined by RT-PCR and Western immunoblotting, respectively. For Western blot studies 
two distinct podoplanin antibodies that recognize the protein ectodomain were used, as 
described in Materials and methods. 
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CGA AAA ATG TCG GGA AGG TAC TC gtaa .... tttccag G CCC TAA 
 YS present YS absent Total 
Human EST database 59 (73%)  21 (27%)  80 
Lung 18 (45%)  15 (55%)  33 
NCCIT cell line 3 (42%)  4 (58%)  7 
 
Homo sapiens (human) RKMSGRYSP 
Pan troglodites (chimpanze) RKMSGRYSP 
Macaca mulatta (rhesus monkey) RKMSGRYSP 
Bos taurus (cow) RKM-GRYSP 
Canis gamiliaris (dog) RKMSGRYSP 
Felis catus (cat) RKMSGRYSP 
Loxodonta africana (elephant) RKMSGRYSP 
Sus scrofa (pig) RKMSGRYSP 
Mus musculus (mouse) KKISGRFSP 
Rattus norvegicus (rat) RKISGRFSP 
Cricetulus griseus (chinese hamster) KKISGRYSP 
Gallus domesticus (chicken) RKMSGRYSP 
Ambystoma mexicanum (axolotl) KKMSGRYSP 
Danio rerio (zebrafish) RRM-GQYSP 
Gasterosteus aculeatus (stickleback) RRM-GKYSP 
Salmo trutta (brown trout) RRM-GKYSP 
Oryzias latipes (Japanese medaka)  RRM-GKYSP 
Takifugu rubripes (pufferfish)  RRM-GKYSP 
Tetraodon nigroviridis (spotted green pufferfish) KRM-GKYSP 
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